JPRN-UMIN000035853Completed未知
Retrospective study of alectinib on long-term prognosis in poor performance status patients with ALK positive, advanced/recurrent NSCLC - LOGIK1401-B
ung Oncology Group in Kyushu, Japan (LOGIK)0 sites18 target enrollmentStarted: February 12, 2019Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 18
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Nothing particular
Investigators
Similar Trials
Completed
Phase 2
A-LiquidJPRN-jRCT2080225060Department of Thoracic Oncology, National Cancer Center Hospital East25
Completed
Not Applicable
PhaseII safety and efficacy study of alectinib in poor performance status patients with ALK positive, advanced NSCLCon-Small Cell Lung CancerJPRN-UMIN000015094ung Oncology Group in Kyushu, Japan (LOGIK)17
Completed
Phase 4
Prospective study on effects of abrocitinib treatment of moderate to severe atopic dermatitis on skin barrier functioL20.9Atopic dermatitis, unspecifiedDRKS00028981niversitätsklinikum Schleswig-Holstein, Campus Kiel, Abteilung für Dermatologie, Allergologie und Venerologie20
Recruiting
Not Applicable
Retrospective study for Lenvatinib for unresectable thyroid cancersnresectable thyroid cacersJPRN-UMIN000030969Kyoto Prefectural University of Medicine50
Completed
Not Applicable
The Efficacy and Safety of Alectinib in Clinical Practice ; Comparision to Crizotinib, in A Multicenter Retrospective Study.ALK rearranged non-small-cell lung cancerJPRN-UMIN000036255Respiratory Centor, Matsusaka Municipal Hospital61